A Novel H2S-releasing Amino-Bisphosphonate which combines bone anti-catabolic and anabolic functions.

ABSTRACT: Bisphosphonates (BPs) are the first-line treatment of bone loss resulting from various pathological conditions. Due to their high affinity to bone they have been used to develop conjugates with pro-anabolic or anti-catabolic drugs. We recently demontrated that hydrogen sulfide (H₂S), promotes osteogenesis and inhibits osteoclast differentiation. Here we developed an innovative molecule, named DM-22, obtained from the combination of alendronate (AL) and the H₂S-releasing moiety aryl-isothiocyanate. DM-22 and AL were assayed in vitro in the concentration range 1-33 μM for effects on viability and function of human osteoclasts (h-OCs) and mesenchymal stromal cells (h-MSCs) undergoing osteogenic differentiation. Amperometric measures revealed that DM-22 releases H_2</

SUBMITTER: Rapposelli S 

PROVIDER: S-EPMC5607332 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature